S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:FLXN

Flexion Therapeutics - FLXN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$9.12
$9.12
50-Day Range
$9.12
$9.44
52-Week Range
$4.30
$13.66
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$458.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FLXN stock logo

About Flexion Therapeutics (NASDAQ:FLXN) Stock

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FLXN Stock News Headlines

PCRX Pacira BioSciences, Inc.
Coherus BioSciences Inc. News
See More Headlines

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FLXN Company Calendar

Last Earnings
5/12/2021
Today
12/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLXN
Employees
257
Year Founded
N/A

Profitability

Net Income
$-113,710,000.00
Net Margins
-100.32%
Pretax Margin
-100.32%

Debt

Sales & Book Value

Annual Sales
$85.55 million
Book Value
($0.34) per share

Miscellaneous

Free Float
45,727,000
Market Cap
$458.93 million
Optionable
Optionable
Beta
1.53

Key Executives

  • Michael D. Clayman
    President, Chief Executive Officer & Director
  • Fred Driscoll
    Chief Financial Officer
  • William T. Andrews
    Chief Medical Officer
  • Carolyn Beaty Scimemi
    Chief Compliance Officer & Head-Legal Affairs
  • Christina WillwerthChristina Willwerth
    Chief Strategy Officer













FLXN Stock - Frequently Asked Questions

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) issued its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analysts' expectations of $24.61 million.

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $9.12.

How much money does Flexion Therapeutics make?

Flexion Therapeutics (NASDAQ:FLXN) has a market capitalization of $458.93 million and generates $85.55 million in revenue each year. The specialty pharmaceutical company earns $-113,710,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Flexion Therapeutics have?

The company employs 257 workers across the globe.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The official website for the company is www.flexiontherapeutics.com. The specialty pharmaceutical company can be reached via phone at (781) 305-7777, via email at ir@flexiontherapeutics.com, or via fax at 781-202-3399.

This page (NASDAQ:FLXN) was last updated on 12/1/2022 by MarketBeat.com Staff